世界のがん腫瘍オルガノイド市場(~2025):モデリング・技術・個別化がんリサーチインサイト

◆英語タイトル:Global Cancer Tumor Organoids Modeling, Technology and Personalized Cancer Research Insight 2025
◆商品コード:KUIK21FB020
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2020年1月
◆ページ数:300
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD3,300 ⇒換算¥376,200見積依頼/購入/質問フォーム
Multi UserUSD6,000 ⇒換算¥684,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界のがん腫瘍オルガノイド市場について調査・分析を行い、イントロダクション、癌オルガノイド、ヒト癌モデリング、癌オルガノイドの確立、癌オルガノイド&その他の実験技術の治療反応、癌治療を加速する腫瘍オルガノイド、癌オルガノイドの利点、高度研究&治療の可能性、基礎医学研究におけるオルガノイド開発、がんオルガノイドのモデル生成後スクリーニング、患者由来腫瘍オルガノイド&医学研究におけるその成果、CRISPR-Cas9の癌オルガノイドへの応用可能性、膵臓癌研究用癌オルガノイド、胃がん研究用癌オルガノイド、癌生物学における肝臓オルガノイドの三次元培養、乳がんオルガノイドの高度開発、腎臓癌オルガノイドの高度開発、肺がんオルガノイドの高度開発、卵巣癌オルガノイドの高度開発、市場要因・課題、今後の方向性、臨床試験、競争状況などを掲載しています。
・イントロダクション
・癌オルガノイド
・ヒト癌モデリング
・癌オルガノイドの確立
・癌オルガノイド&その他の実験技術の治療反応
・癌治療を加速する腫瘍オルガノイド
・癌オルガノイドの利点
・高度研究&治療の可能性
・基礎医学研究におけるオルガノイド開発
・がんオルガノイドのモデル生成後スクリーニング
・患者由来腫瘍オルガノイド&医学研究におけるその成果
・CRISPR-Cas9の癌オルガノイドへの応用可能性
・膵臓癌研究用癌オルガノイド
・胃がん研究用癌オルガノイド
・癌生物学における肝臓オルガノイドの三次元培養
・乳がんオルガノイドの高度開発
・腎臓癌オルガノイドの高度開発
・肺がんオルガノイドの高度開発
・卵巣癌オルガノイドの高度開発
・市場要因・課題
・今後の方向性
・臨床試験
・競争状況
【レポートの概要】

“Global Cancer Tumor Organoids Modeling, Technology and Personalized Cancer Research Insight 2025″ Report Highlights:

Application of Organoids by Cancer Therapeutic
CRISPR-Cas9 Potential Applications in Cancer Organoids
Cancer Organoid Market Opportunity Assessment:: US$ 400 Million
Clinical Trials Registered under Cancer Organoids
Personalized Cancer Therapy Using Cancer Organoids
Joint Ventures to Accelerate Drug Discovery through Organoids

The development of cancer organoids has transformed the widespread adoption of the traditional 2D cell lines in the research community. The technology of cancer organoids holds a significant potential to study variety of areas such as cancer disease pathology, cancer biology, precision medicine, drug development, drug testing and drug efficacy testing. For the mentioned areas, cancer organoid technology constitutes tremendous informative complimentary approaches to the already available two-dimensional culture method and animal model system.

“Report Highlights The Ongoing Clinical Advancement In Cancer Organoids and Helps To Identify The Application Of Organoids Platform Across Multiple Cancers In Order To Develop More Personalized Cancer Therapy and Drug Screening”

On an average, the development of organoid culture represents a novel technology for studying human disease and human development. The ability of the organoids to resemble the original human tissue, form the correct type of cell and to perform the specific functions of the tissues helps in gaining the confidence of working on human cancer organoids and for the development of treatments against human cancers. Cancer organoids faithfully recapitulate the different aspects of tissue composition, function and architecture ex vivo and by doing so they set a great example of an advanced technology that comes with the possibility of opening up and identifying novel therapeutics strategies in personalizing the human disease model.

“The Organoid Technology Has The Advantage Of Predicting The Accurate Response Than Any Other 2D Cell Culture Models Available. It Carries Better Capacity To Unravel The Heterogeneity Within Individual Patients And Is Combined With High Throughput Screening Technology Than The Xenografts Model”

All this advancement should enable the cancer organoid technology to develop its place at the top and marking itself as an important tool in predicting the response of the cancer patients towards cancer treatment in the future. Till now, majority of the cancer organoids have been generated for adenocarcinomas and very less organoids are currently available for the squamous cell carcinomas. Since the development of cancer organoids from the cancer tumors in vivo, it has opened up new avenues for the investigation and identification of new drugs and treatments. As organoids can be developed from various types of cancer, therefore it offers a great potential towards investigating treatment responses in the patient personally and therefore is expected to provide a better insight into the precision medicine in the future.

For the future research, organoid technology is expected to present a crucial position and it is undoubtedly successful in revolutionizing the technical, preclinical and clinical techniques adapted in the laboratories. The technology of developing a complete organ in vitro from small amount of cells is considered as groundbreaking as the discovery of antibiotics, vaccines and chemotherapy in the fight against different human diseases. The technology requires few years and some advancement, to be dominant over the other available technologies.

【レポートの目次】

1. Introduction to Organoids
1.1 Organoids
1.2 History of the Development
1.3 Timeline for Patient Derived Tumor Organoid (PDTO) Development

2. Cancer Organoids: Promising Tool for Cancer Biologists
2.1 Cancer Organoids Revealing the Cancer Dynamics
2.2 Cancer Organoids: An Intermediate Platform for Targeted Therapy

3. Human Cancer Modeling
3.1 Growth Factors and Small Molecule Inhibitors Applied In Organoid Cultures
3.2 Culture Systems of Multiple Tumoroids
3.3 Human Organoid Protocol
3.4 Extraction Methods for Initiating an Organoid Generation
3.4.1 Biopsy
3.4.2 Surgery

4. Establishment of Cancer Organoids
4.1 In-vitro Establishment of Stomach Cancer Organoid Cancer
4.2 Invasion of In-Vivo Mutations in In-Vitro Organoid Model of Intestinal Cancer
4.3 Expansion of Liver Cancer Organoids in the Laboratories
4.4 In- Vitro Modeling of Pancreatic Cancer Organoid
4.5 Transformation of Breast Cancer Cells into Organoids
4.6 3D Organoid Model Generation for Bladder Cancer
4.7 Obtaining In-Vitro Model of In-Vivo Prostate Cancer
4.8 Miniature Organ Development from the In-Vivo Ovarian Cancer Cells
4.9 Creation of In-Vivo Esophageal Cancer as an In-Vitro Organoid Model

5. Cancer Organoids and Other Laboratory Techniques to Assess Treatment Responses
5.1 Cell Lines
5.2 Patient-Derived Xenografts
5.3 Organotypic Tissue Slice Culture
5.4 Cancer Organoids: Marking a New Territory

6. Tumors Organoids Accelerating Cancer Treatment
6.1 Cancer Epidemic and Pre-Screening
6.2 Cancer Organoids Predicting Tumor Responses

7. Advantages of Cancer Organoids
7.1 Reduction in Experimental Complexity Through Cancer Organoids Models
7.2 Similar Genetic Representation between the Organoid and Parent Tumor Organ
7.3 Cancer Organoid Models Predicting the Response of Cancer Treatment
7.4 Cancer Organoid Models Retaining the Phenotype of Parent Organ after Development
7.5 Cancer Organoid Models Supporting Biomarker Profiling in Cancer Research

8. Cancer Organoids: Advanced Research and Therapeutic Potential
8.1 Cancer Organoids: Revolutionizing Novel Anti-Cancer Drug Testing Methodology
8.2 Mini-Organ Toxicity Demonstration by Cancer Organoids
8.3 Pharmacokinetics and Pharmacodynamics Analysis Enabled by Cancer Organoids
8.4 Cancer Organoids: Innovations in Drug Development Method
8.5 Cancer Organoids as a Potential Platform for Personalized Cancer Therapy

9. Organoid Development Transforming Basic Medical Research
9.1 Organoids Advancement in Organ Replacement
9.2 Analyzing Gene Therapy on Organoids
9.3 Organoids for Cell Therapy Analysis

10. Post-Model Generation Screening of Cancer Organoids
10.1 Identical Genetic Characteristics between Cancer Organoid and Parent Organ
10.2 Maintaining the Histology of Cancer Organ Tissues
10.3 Tumorigenic Characteristic Screening of Cancer Organoids

11. Patient-Derived Tumor Organoids and its Achievement in Medical Research
11.1 Translational Application of Cancer organoid Models
11.2 Cancer Organoids Promoting Oncogenic Mutation Study
11.3 Integration of the Microenvironment Induced by Cancer Organoids

12. CRISPR-Cas9 Potential Applications in Cancer Organoids
12.1 CRISPR-Cas9: A Promising Gene Editing Technology
12.2 CRISPR-Cas9 Mediated Cancer Organoid Technology
12.3 CRISPR Based Gene Edited Organoids Recapitulating Cancer Mutations

13. Organoids for the Study of Pancreatic Cancer
13.1 Human Endocrine and Exocrine Cancer Pancreatic 3D Model to Transform Cancer Treatment
13.2 Development of Pancreas 3D Cancer Organoid System
13.3 Applications of 3D Pancreatic Organoid Culture
13.3.1 Pancreatic Cancer Organoid and Genetic Implementation
13.3.2 Pancreatic Cancer Organoid and the Inner Environment Benefits
13.3.3 Pancreatic Cancer Organoid Model for Drug Toxicity Screening
13.3.4 Pancreatic Cancer Organoid Provoking Personalized Therapy

14. Organoids for the Study of Stomach Cancer
14.1 Development of Stomach Cancer Organoid Culture
14.2 High-Throughput Screening with Stomach Cancer Organoid 3D Model
14.2.1 Tumorigenesis with Stomach Cancer Organoids
14.2.2 Stomach Cancer Organoids Screening Drug Sensitivity
14.2.3 Developing Stomach Cancer Biobanks for Drug Screening
14.2.4 Stomach Cancer Organoids for Personalizing Therapy

15. Three-Dimensional Culture of Liver Organoid in Cancer Biology
15.1 Development of Liver Organoids
15.2 Progress and Potential of Organoid Towards Liver Cancer
15.2.1 Liver Cancer Organoids as a New Model for Improving Drug Screening
15.2.2 Primary Liver Cancer Organoids for Novel Drug Discovery
15.2.3 Primary Liver Cancer Organoids Creating the Living Biobank for the Future Therapeutic Challenges
15.2.4 Primary Liver Cancer Organoids Transforming Personalized Therapy

16. Advanced Development of Breast Cancer Organoids
16.1 Organoid Technology to Transform Breast Cancer Modeling and Development
16.2 An Organoid Approach Marking Breast Cancer Therapeutic Research
16.2.1 Breast Cancer Organoids in Drug Development and Expansion
16.2.2 Breast Cancer Organoids: An in-vitro Model for Cancer Biomarker Discovery
16.2.3 Breast Cancer Organoids as a Powerful Resource for Personalized Therapy

17. Kidney Cancer Organoids for Cancer Research and Therapeutic Challenges
17.1 Kidney Cancer Organoids: Developmental Approach and Characteristics Analysis
17.2 Organoid Technology and its Applications in Treating Kidney Cancer
17.2.1 Kidney Cancer Organoids Actively Participating in the Pre-Clinical and Clinical Trials
17.2.2 Validation of Cancer Biomarkers by Kidney Cancer Organoids in Drug Development

18. Organoids for the Development of Lung Cancer
18.1 Generation of Lung Cancer Organoid from Lungs Tissue
18.2 Lung Cancer Organoids: A Novel 3D Platform for Therapeutic Research
18.2.1 Lung Cancer Organoids for Therapeutic Screening and Cancer Research
18.2.2 Organoids Re-Creating the Treatment for Lung Cancer

19. Ovarian Cancer Organoids and its role in Therapeutic Advancement
19.1 Organoid Model Recapitulating Human Ovarian Cancer
19.2 Validation of Potential Benefits Received from Patient-Derived Ovarian Cancer Organoid Model
19.2.1 Editing of Oncogenes in the Patient Derived Ovarian Cancer Organoids
19.2.2 Screening and Drug Testing on Human Ovarian Cancer Organoid Model
19.2.3 Ovarian Cancer Organoids in Modeling the Ovarian Cancer Development and Progression

20. An Organoid Platform for Oncological Research in Bladder Cancer
20.1 Establishment of High-Resolution 3D Organoid Model for Bladder Cancer
20.2 Efficient Use of 3D Bladder Cancer Organoids in Oncology Landscape
20.2.1 3D Bladder Cancer Organoids at an Uprising Scale for Drug Discovery
20.2.2 Testing and Screening of Drugs using Bladder Cancer Organoids
20.2.3 Patient-Derived Bladder Cancer Organoids Predicting Response to Various Cancer Treatments

21. Human Primary Head and Neck Cancer: An Organoid Approach for In-depth Clinical Research
21.1 Generation and Culture of 3D Head and Neck Cancer Organoids
21.2 Patient-Derived Head and Neck Cancer Organoids Re-defining the Cancer Research
21.2.1 Broad Activity of Head and Neck Cancer Organoids towards Cancer Modeling
21.2.2 Transformation of Drug Development and Drug Efficacy Strategies in Head and Neck Cancer using Organoid Technology

22. Living Biobanks of Cancer Organoids Representing Histopathological Diversity
22.1 The Potential of Living Biobank towards Precision Medicine
22.2 Living Bio-banking Strategy Offering Novel Therapeutics for Basic and Advanced Cancer Research

23. Drivers and Challenges Associated with Cancer Organoids
23.1 Drivers Witnessing the Growth of Cancer Organoid Technology
23.2 Challenges Concerning the Growth of Cancer Organoids

24. Future Directions of Organoids in Cancer Research

25. Strategic Joint Ventures by Pharma Companies to Accelerate Drug Discovery through Organoids
25.1 Expanded Breast Cancer Organoids License Agreement between Cellesce and Hubrecht Organoid Technology
25.2 Pre-Clinical Anti-Cancer Drug Development between HUB Organoid Technology and Crown Biosciences
25.3 SEngine’s and Atomwise’s New Joint Venture to Boost Drug Discovery through Organoids

26. Clinical Trials Registered under Cancer Organoids
26.1 Lung Cancer
26.1.1 Clinical Trial – Patient-Derived Organoids of Lung Cancer to Test Drug Responses
26.1.2 Clinical Trial – Patient-Derived Organoid Model and Circulating Tumor Cell for Treatment Responses of Lung Cancer
26.1.3 Clinical Trial – Drug Sensitivity Correlation between Patient-Derived Organoid Model and Clinical Responses in Non-Small Cell Lung Cancer Patients
26.2 Breast Cancer
26.2.1 Clinical Trial – Clinical Study on Drug Sensitivity Verification or Prediction for Breast Cancer by Patient-Derived Organoid Model
26.3 Pancreatic Cancer
26.3.1 Clinical Trial – Drug Screening of Pancreatic Cancer Organoids Developed from EUS-FNA Guided Biopsy Tissues
26.4 Esophageal Cancer
26.4.1 Clinical Trial – Chemoradioresistnace in Prospectively Isolated Cancer Stem Cells in Esophageal Cancer – Organoid: RARE STEM Organoid

27. Current Market Scenario of Cancer Organoid Technology
27.1 Market Trends
27.2 Market Overview
27.2.1 North America
27.2.2 Europe
27.2.3 Asia-Pacific

28. Competitive Landscape
28.1 Cellesce
28.2 MIMETAS
28.3 Hubrecht Organoid Technology
28.4 Crown Biosciences
28.5 Atomwise
28.6 STEMCELL Technologies
28.7 Qgel
28.8 OcellO
28.9 DefiniGEN



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のがん腫瘍オルガノイド市場(~2025):モデリング・技術・個別化がんリサーチインサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆